Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Active, not recruiting · NCT01089101 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioma, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, low grade glioma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neuroepithelial neoplasm, neurofibroma, neurofibromatosis, neurofibromatosis type 1, neuromuscular disease, peripheral nervous system disorder, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-21 | NCT01089101 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
17 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.